<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml">
	<head>
		<meta charset="utf-8" />
		<title>BCSC1819_S06_C22_p277-292</title>
		<link href="BCSC1819_S06_C22_p277-292-web-resources/css/idGeneratedStyles.css" rel="stylesheet" type="text/css" />
	</head>
	<body id="BCSC1819_S06_C22_p277-292" lang="en-US">
		<div id="_idContainer007" class="Basic-Text-Frame">
			<p class="chapter-number"><span class="cn-chap">Chapter</span><span class="cn-chap"> </span>22</p>
			<p class="chapter-title">Pediatric Glaucomas</p>
			<p class="video-list-mid ParaOverride-1"><img class="_idGenObjectAttribute-1" src="data:image/png;base64,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" alt="" />&#9;<span class="italic">This chapter includes related videos, which can be accessed by scanning the QR codes provided in the text or &#173;going to </span><a href="http://www.aao.org/bcscvideo_section06"><span class="Hyperlink">www.aao.org/bcscvideo_section06</span></a><span class="italic">.</span></p>
			<p class="body-text--no-indent-">Pediatric glaucomas are a heterogeneous group of diseases that may result from an isolated congenital abnormality of the aqueous outflow pathways (primary glaucoma) or from abnormalities affecting other regions of the eye (secondary glaucoma). A variety of systemic conditions are associated with pediatric glaucoma. See BCSC Section&#160;10, <span class="italic">Glaucoma,</span> for additional discussion of topics covered in this chapter.</p>
			<p class="h1 ParaOverride-2">Classification</p>
			<div id="Chapt22_Top1">
			<p class="body-text--no-indent-">In 2013, an international classification system for childhood glaucoma was established by the Childhood Glaucoma Research Network and the World Glaucoma Association. In the classification system, <span class="italic">childhood glaucoma</span> is defined as intraocular pressure (IOP)–&#173;related damage to the eye as opposed to IOP-&#173;related damage to the optic nerve, which defines adult glaucoma. This classification is summarized in <span class="xref-table">&#173;Table&#160;22-1</span>, and an algorithm for classifying a patient with childhood glaucoma using &#173;these criteria is presented in <span class="xref-figure">Figure&#160;22-1</span>.</p>
			<p class="reference--journal--single">Beck AD, Chang TCP, Freedman SF. Definition, classification, differential diagnosis. In: Weinreb RN, Grajewski AL, Papadopoulos M, Grigg J, Freedman S, eds. <span class="italic">Childhood Glaucoma.</span> Amsterdam: Kugler Publications; 2013:3–10. <span class="italic">World Glaucoma Association Consensus Series—9.</span></p>
			</div>
			<p class="h1 ParaOverride-2">Genetics</p>
			<div id="Chapt22_Top2">
			<p class="body-text--no-indent-">Although primary congenital glaucoma (PCG) usually occurs sporadically, it may be inherited as an autosomal recessive trait. When no other &#173;family history of PCG exists, the chance of an affected parent having a child with PCG is approximately 2%. Four chromosomal loci for PCG have been identified: GLC3A on band 2p21, GLC3B on 1p36, GLC3C on 14q24.3, and GLC3D on 14q24.3. Mutations in <span class="italic">CYP1B1</span> (at the GLC3A locus) have been shown to cause PCG. Populations in which consanguinity is common, especially &#173;those in which the carrier rate of the <span class="italic">CYP1B1</span> gene is high, have higher incidences of PCG. Individuals who carry the <span class="italic">CYP1B1</span> gene but who are nonpenetrant for PCG remain at higher risk for adult-&#173;onset glaucoma. <span class="italic">LTBP2</span> mutations (at the GLC3D locus) cause a primary megalocornea with zonular weakness, forward displacement of the lens, and a secondary glaucoma that responds poorly to standard &#173;angle surgery. In this condition, the preferred treatment is lens removal.</p>
			<p class="body-text">Juvenile open-&#173;angle glaucoma is inherited as an autosomal dominant trait and has been linked to the GLC1A myocilin gene <span class="italic">(MYOC),</span> which is also responsible for some forms of adult open-&#173;angle glaucoma.</p>
			<p class="body-text">The ge&#173;ne&#173;tic &#173;causes of many conditions associated with secondary childhood glaucoma have been identified; they are discussed in the chapters associated with their primary conditions.</p>
			<p class="reference--journal--single">Khan AO, Aldahmesh MA, Alkuraya FS. Congenital megalocornea with zonular weakness and childhood lens-&#173;related secondary glaucoma—&#173;a distinct phenotype caused by recessive <span class="italic">LTBP2</span> mutations. <span class="italic">Mol Vis.</span> 2011;17:2570–2579.</p>
			</div>		
			<p class="h1">Primary Childhood Glaucoma</p>
			<div id="Chapt22_Top3">
			<p class="h2-h1">Primary Congenital Glaucoma</p>
			<p class="body-text--no-indent-">Primary congenital glaucoma (PCG; also called <span class="italic">congenital</span> or <span class="italic">infantile glaucoma</span>) is the most common form of childhood glaucoma. The incidence of PCG varies in dif&#173;fer&#173;ent populations, ranging from 1&#160;in 1250 live births to 1&#160;in 68,000. PCG occurs more frequently in males (65% of cases), and it is bilateral in about two-&#173;thirds of patients. PCG results in blindness in 2%–15% of cases, and visual acuity remains worse than 20/50&#160;in at least 50% of cases.</p>
			<p class="body-text">Although the diagnosis is made at birth in only 25% of affected infants, disease onset occurs within the first year of life in more than 80% of cases. Neonatal-&#173;onset and late-&#173;recognized PCG are associated with guarded prognoses.</p>
			<p class="h3">Pathophysiology</p>
			<p class="body-text--no-indent-">The basic pathologic defect is increased re&#173;sis&#173;tance to aqueous outflow through the trabecular meshwork due to abnormal development of neural crest–&#173;derived tissue of the anterior chamber &#173;angle. The anomaly occurs late in embryologic development.</p>
			<p class="h3">Clinical manifestations</p>
			<p class="body-text--no-indent-">Primary congenital glaucoma usually pres&#173;ents in the neonatal period or within the first 2&#160;years of life <span class="italic">(infantile PCG),</span> but it can pres&#173;ent or be recognized &#173;after 2&#160;years of age (<span class="italic">late-&#173;onset</span> or <span class="italic">late-&#173;diagnosed PCG</span>). Epiphora, photophobia, and blepharospasm constitute the classic clinical triad of PCG. A red eye may be pres&#173;ent. Other signs include clouding and enlargement of the cornea (<span class="xref-figure">Fig 22-2</span>).</p>
			<p class="body-text">Corneal edema results from elevated IOP and may be gradual or sudden in onset. Corneal edema is often the presenting sign in infants younger than 3 months and is responsible for the clinical triad. Microcystic edema initially involves the corneal epithelium but &#173;later extends into the stroma, often accompanied by one or more curvilinear breaks in Descemet membrane <span class="italic">(Haab striae)</span> (<span class="xref-figure">Fig 22-3</span>). Although the edema may resolve with IOP reduction, the split in Descemet membrane persists. Significant corneal scarring and per&#173;sis&#173;tent opacification may require penetrating keratoplasty. Corneal enlargement occurs with gradual stretching of the cornea as a result of elevated IOP.</p>
			<p class="body-text">The signs and symptoms of PCG can occur in infants with other forms of glaucoma as well. Nonglaucomatous conditions may also cause some of the signs and symptoms seen in PCG (<span class="xref-table">&#173;Table&#160;22-2</span>).</p>
			<p class="h3">Diagnostic examination</p>
			<p class="body-text--no-indent-">A full ophthalmologic examination of &#173;every child suspected of having glaucoma is imperative, despite the challenges. Both office examination and examination &#173;under general anesthesia are usually required. Although visual field testing is helpful in following disease progression in older &#173;children, results of &#173;these tests are rarely reliable in &#173;children younger than 6–8&#160;years. Vision is usually poorer in the affected eye in unilateral cases and may be poor in both eyes when glaucoma is bilateral. Fixation and following be&#173;hav&#173;ior and the presence of nystagmus should be noted. Refraction, when pos&#173;si&#173;ble, often reveals myopia and astigmatism from eye enlargement and corneal irregularity.</p>
			<p class="h4-text"><span class="h4-head">Cornea</span> The cornea should be examined for size, clarity, and Haab striae. In newborns, the normal horizontal dia&#173;meter of the cornea is 9.5–10.5&#160;mm; a dia&#173;meter greater than 11.5&#160;mm suggests glaucoma. By age 1 year, the normal corneal dia&#173;meter is 10.0–11.5&#160;mm; a dia&#173;meter greater than 12.5&#160;mm suggests abnormality. Glaucoma should be suspected in any child with a corneal dia&#173;meter greater than 13.0&#160;mm. A difference as small as 0.5&#160;mm between the 2 eyes may be significant. Haab striae are best seen against the red reflex &#173;after pupil dilation (see <span class="xref-figure">Fig 22-3B</span>).</p>
			<p class="h4-text"><span class="h4-head">Central corneal thickness</span> Portable ultrasonic pachymeters may be used to mea&#173;sure central corneal thickness (CCT), which is typically higher in infants with glaucoma. CCT affects the IOP mea&#173;sure&#173;ment, but current evidence is inadequate to quantify &#173;these effects. See also Chapter&#160;15.</p>
			<p class="h4-text"><span class="h4-head">Tonometry</span> If the child is struggling during mea&#173;sure&#173;ment of IOP, pressure readings may be falsely elevated. Examination &#173;under sedation or anesthesia may be necessary in &#173;children for accurate assessment, but IOP can also be unpredictably altered (usually lowered) with anesthetics and sedation. A useful technique to avoid &#173;these issues is to have the parent bottle-&#173;feed the infant during pressure mea&#173;sure&#173;ment. In infants and young &#173;children, the most commonly used tonometers are Icare (Icare Finland Oy, Helsinki, Finland), Tono-&#173;Pen (Reichert Technologies, Depew, NY), and Perkins (Haag-&#173;Streit USA, Mason, OH). Goldmann applanation readings are preferred when a child is old enough to cooperate.</p>
			<p class="body-text">The normal mean IOP in infants and young &#173;children is lower than that in adults: between 10 and 12&#160;mm Hg in newborns and approximately 14&#160;mm Hg by age 7–8&#160;years. In PCG, IOP commonly ranges between 30 and 40&#160;mm Hg, and it is usually greater than 20&#160;mm Hg even with the patient &#173;under anesthesia. Asymmetric IOP readings in a quiet or anesthetized child should raise suspicion of glaucoma.</p>
			<p class="h4-text"><span class="h4-head">Anterior segment</span> A portable slit lamp enables detailed examination of the anterior segment. An abnormally deep anterior chamber and hypoplasia of the peripheral iris stroma are common findings in PCG.</p>
			<p class="body-text">Gonioscopy provides impor&#173;tant information about the mechanism of glaucoma. A direct (Koeppe-&#173;type) goniolens is preferred for examining &#173;children. The anterior chamber &#173;angle of a normal infant eye (<span class="xref-figure">Fig 22-4A</span>) differs from that of an adult’s eye in the following ways:</p>
			<ul>
				<li class="bullet-list-first ParaOverride-3">The trabecular meshwork is more lightly pigmented.</li>
				<li class="bullet-list-mid ParaOverride-3">The Schwalbe line is often less distinct.</li>
				<li class="bullet-list-last ParaOverride-3">The uveal meshwork is translucent, so the junction between the scleral spur and the ciliary body band is often not well seen.</li>
			</ul>
			<p class="body-text--no-indent-">In an eye with PCG, the iris often shows a more anterior insertion compared with the insertion in a normal infant eye, and the translucence of the uveal meshwork is altered, making the ciliary body band, trabecular meshwork, and scleral spur indistinct (<span class="xref-figure">Fig 22-</span><span class="xref-figure">4B</span>). The scalloped border of the iris pigment epithelium is often unusually prominent, especially when peripheral iris stromal hypoplasia is pres&#173;ent.</p>
			<p class="h4-text"><span class="h4-head">Optic nerve</span> In PCG, the optic nerve, when vis&#173;i&#173;ble, usually shows increased cupping. Generalized enlargement of the optic cup in very young patients with glaucoma has been attributed to stretching of the optic canal and backward bowing of the lamina cribrosa. In most eyes with PCG, the cup–&#173;disc ratio exceeds 0.3, whereas in most normal newborn eyes, the cup–&#173;disc ratio is less than 0.3. Cup–&#173;disc asymmetry greater than 0.2 between the 2 eyes is also suggestive of glaucoma. In young &#173;children, optic nerve cupping may be reversible if IOP is lowered (<span class="xref-figure">Fig 22-5</span>). Whenever pos&#173;si&#173;ble, photo&#173;graphs should be taken of the optic disc for comparison during &#173;later examinations.</p>
			<p class="h4-text"><span class="h4-head">Axial length</span> Serial mea&#173;sure&#173;ment of axial length is useful for monitoring disease progression in infant eyes. Excessive axial length in an eye, especially compared with the fellow eye, may indicate inadequate IOP control.</p>
			<p class="h4-text"><span class="h4-head">Optical coherence tomography</span> Newer methods of optic nerve and ret&#173;i&#173;nal nerve fiber analy&#173;sis, such as optical coherence tomography (OCT), are being used as objective tools for follow-up of &#173;children with elevated IOP and glaucoma. Macular thickness, ret&#173;i&#173;nal nerve fiber layer thickness, and optic nerve topography have been shown to vary with race, axial length, and age in &#173;children, but normative data are becoming available, which should further increase the usefulness of OCT in the assessment of pediatric glaucoma.</p>
			<p class="reference--journal--first">El-&#173;Dairi MA, Asrani SG, Enyedi LB, Freedman SF. Optical coherence tomography in the eyes of normal &#173;children. <span class="italic">Arch Ophthalmol.</span> 2009;127(1):50–58.</p>
			<p class="reference--journal--last">Prakalapakorn SG, Freedman SF, Lokhnygina Y, et&#160;al. Longitudinal reproducibility of optical coherence tomography mea&#173;sure&#173;ments in &#173;children. <span class="italic">J AAPOS.</span> 2012;16(6):523–528.</p>
			<p class="h3">Natu&#173;ral history</p>
			<p class="body-text--no-indent-">Untreated PCG almost always progresses to blindness. The cornea irreversibly opacifies and may vascularize. It may continue to enlarge through the first 2–3&#160;years of life, reaching a dia&#173;meter of up to 17&#160;mm. As the entire eye enlarges, pseudoproptosis and an “ox eye” appearance (buphthalmos) may result. Scleral thinning and myopic fundus changes may occur, and spontaneous lens dislocation can result. Optic nerve damage progresses, leading to complete blindness. However, rare cases of spontaneous resolution have been&#160;reported.</p>
			<p class="h2 ParaOverride-4">Juvenile Open-&#173;Angle Glaucoma</p>
			<p class="body-text--no-indent-">Juvenile open-&#173;angle glaucoma (JOAG) is an autosomal dominant condition that pres&#173;ents &#173;after 4&#160;years of age. Unlike in late-&#173;recognized PCG, the cornea is not enlarged, Haab striae are not pres&#173;ent, and the anterior chamber &#173;angle usually appears normal. Management of JOAG is similar to that of adult primary open-&#173;angle glaucoma, but the condition frequently requires surgery. See BCSC Section&#160;10, <span class="italic">Glaucoma,</span> for management of adult glaucoma.</p>
			</div>
			<p class="h1 ParaOverride-5">Secondary Childhood Glaucoma</p>
			<div id="Chapt22_Top4">
			<p class="body-text--no-indent-">Glaucoma caused by other ocular anomalies (congenital or acquired) or associated with systemic disease or syndromes is considered secondary. <span class="xref-table">&#173;Table&#160;22-3</span> lists nonacquired ocular anomalies and systemic diseases and syndromes associated with secondary glaucoma.</p>
			<p class="h2 ParaOverride-4">Secondary Glaucoma Associated With an Acquired Condition</p>
			<p class="body-text--no-indent-">In &#173;children, as in adults, glaucoma may develop secondary to corticosteroid use, uveitis, infection, or ocular trauma. The anticonvulsant and antidepressant medi&#173;cation topiramate can cause acute, usually bilateral, angle-&#173;closure glaucoma secondary to ciliary effusion. The ciliochoroidal effusion &#173;causes relaxation of zonules, resulting in extreme anterior displacement of the lens–&#173;iris complex, which leads to secondary angle-&#173;closure glaucoma and high myopia. Peripheral iridectomy is not effective as treatment, but timely cessation of the medi&#173;cation is.</p>
			<p class="h2">Glaucoma Following Cataract Surgery</p>
			<p class="body-text--no-indent-">Aphakic glaucoma is a common form of secondary glaucoma in childhood. The reported incidence of open-&#173;angle aphakic glaucoma &#173;after congenital cataract surgery varies from 15% to 50% or higher. Aphakic glaucoma often develops years &#173;after cataract surgery, but it can occur within weeks to months of surgery and remains a lifelong risk. Consequently, patients who have under&#173;gone cataract surgery in childhood require regular ophthalmic examination. The &#173;children at highest risk for glaucoma development following cataract surgery are &#173;those who have surgery during infancy, and the risk appears to be even higher in patients with microcornea or per&#173;sis&#173;tent fetal vasculature.</p>
			<p class="body-text">The mechanism of aphakic glaucoma is unclear. The anterior chamber &#173;angle usually appears open on gonioscopy; the outflow channels are compromised by some combination of abnormal development of the anterior chamber &#173;angle and perhaps susceptibility of the infant eye to surgically induced inflammation, loss of lens support, retained lens epithelial cells, or vitreous &#173;factors.</p>
			<p class="body-text">Acute or subacute &#173;angle closure with iris bomb<span class="accent">é</span> is a rare form of aphakic glaucoma. Although it usually occurs soon &#173;after surgery, onset can be delayed by a year or more. The diagnosis should be apparent with a slit lamp, but examination at the slit lamp may be difficult in young &#173;children. Treatment consists of anterior vitrectomy to relieve the pupillary block, often with surgical iridectomy and goniosynechialysis.</p>
			<p class="reference--journal--single">Freedman SF, Lynn MJ, Beck AD, Bothun ED, <span class="accent">Ö</span>rge FH, Lambert SR; Infant Aphakia Treatment Study Group. Glaucoma-&#173;related adverse events in the first 5&#160;years &#173;after unilateral cataract removal in the Infant Aphakia Treatment Study. <span class="italic">JAMA Ophthalmol</span>. 2015;133(8):907–914.</p>
			</div>
			<p class="h1">Treatment</p>
			<div id="Chapt22_Top5">
			<p class="body-text--no-indent-">The primary treatment for most types of childhood glaucoma is surgery. PCG is usually effectively treated with &#173;angle surgery (goniotomy or trabeculotomy). Although &#173;angle surgery may be used to treat some forms of secondary pediatric glaucoma—&#173;most notably, &#173;those associated with Axenfeld-&#173;Rieger syndrome, Sturge-&#173;Weber Syndrome, and aniridia—&#173;the outcome is often less successful. The treatment of most forms of secondary childhood glaucoma (see &#173;Table&#160;22-3) is similar to that of open-&#173;angle or secondary glaucoma in adults. Medical treatment often has value prior to surgery and may have long-&#173;term benefit, particularly in JOAG and some secondary childhood glaucomas.</p>
			<p class="h2">Surgical Therapy</p>
			<p class="body-text--no-indent-">Surgical intervention is the treatment of choice for PCG. Goniotomy or trabeculotomy is the preferred initial procedure. In a <span class="italic">goniotomy,</span> an incision is made, &#173;under direct gonioscopic visualization, across the trabecular meshwork (<span class="xref-figure">Fig 22-6</span>, <span class="xref-video">Video 22-1</span>).</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer001" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first-recto"> <span class="QR-code-number">VIDEO 22-1</span> Goniotomy.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer002" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source-right"><span class="QR-code-source-italic CharOverride-1">Courtesy of Ken&#160;K. Nischal, MD.</span></p>
			<p class="QR-code-text-last-recto">Access all Section&#160;6 videos at <a href="http://www.aao.org/bcscvideo_section06"><span class="Hyperlink">www.aao.org/bcscvideo_section06</span></a>.</p>
			<p class="body-text--no-indent-">In <span class="italic">trabeculotomy,</span> an external approach is used to identify and cannulate the Schlemm canal, and then connect it with the anterior chamber through incision of the trabecular meshwork (<span class="xref-figure">Fig 22-7</span>, <span class="xref-video">Video 22-2</span>).</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer003" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first"> <span class="QR-code-number">VIDEO 22-2</span> Trabeculotomy.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer004" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-source ParaOverride-6"><span class="QR-code-source-italic CharOverride-1">Courtesy of Young&#160;H. Kwon, MD, PhD.</span></p>
			<p class="body-text--no-indent-">A modification of this technique uses a 6-0 polypropylene monofilament suture or illuminated microcatheter to cannulate and open the Schlemm canal for its entire 360° circumference in one surgery (<span class="xref-video">Video 22-3</span>).</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer005" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/jpg;base64,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" alt="" />
				</div>
			</div>
			<p class="QR-code-caption-first-recto ParaOverride-7"> <span class="QR-code-number">VIDEO 22-3</span> Illuminated microcatheter–&#173;assisted 360-&#173;degree trabeculotomy.</p>
			<div class="_idGenObjectLayout-1">
				<div id="_idContainer006" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAADYAAAA2CAYAAACMRWrdAAAACXBIWXMAABcRAAAXEQHKJvM/AAAClUlEQVRoQ+2avcraUBjH3QvdeguC4AcKgouCi6DX4AWIQ8ChFLM0ixkrKF1Eurl0sHRy7E20XbwAoZChWEKhQ5p/eE+JebV/8x6THM+bwG8QT855fvl8Ts5T8Dyv8BQ2m824WCx6SWJZ1nsWxyVog2cjtl6vX7darR/1ev3IApOlWq26GMs0zTWLS1psuVy+ZQHdGsMwPrK4YovZtv1uMBh8FeAIskBuTaPR+BmOYTQafWZxUzEcLTZw2vhy31jcF/+YzWbz4XD4JYszxKjVar8Q23g8/hRbDDuyAbIGB/1qMdxTuPxUPFNRyuXyb8R67uHySAw3J+tQRXKxe+OiGDIK/+Vr3cO9dY7FYmEhftd1X5yI3atQFMdxXgViSGaBbO7XbreRtHqTyYS2TZLVavUGPgXW8Fr89x6uc2+/39O2aSAt1ul0kKTiGg/EDodD8DsM6yMJpMUQONtYH0mQihgu0zB+rkf7lSUVsejmvytpv7JkIubPpwI5gT/fouPEJROx6JbEA0YJMdM0MQX5xy3uQSXEopufGtFxGblYmmLRbbfb0ThysWvJxSQ2bcT8acfJCxyJNovjLsS0eSpiyhNOkrvdLh2XoYSYNimVbdsnE9Gn3EOMTMS0mbbgI0+YZrNJ+5UlFTHWRxJIi+GywuN5u90GEo7jBL/DsD6SQFpMoNznN6zMg0ql4rLG/6PX6wUZw3w+p22TZDqdfoCPvp+4hRhKDrCAhoVstrOKGA8LgMfj8eWJmEC7ZaRcTFGoGIpDUEeBkgPWWdaUSqU/iPVc3ccjMYF25RACFIdgR5QcsAHSBmcKsfX7/e+xxQSGbiVH2otF0aas79mIoY4C+RhW51lAsiChxVgiTYoDbXAJ1WuC/wLOZIWopgEC6wAAAABJRU5ErkJggg==" alt="" />
				</div>
			</div>
			<p class="QR-code-source-right ParaOverride-8"><span class="QR-code-source-italic CharOverride-1">Courtesy of Brenda&#160;L. Bohnsack, MD, PhD.</span></p>
			<p class="body-text--no-indent-">If the cornea is clear, &#173;either a goniotomy or a trabeculotomy can be performed at the surgeon’s discretion. Preoperative glaucoma medi&#173;cations or stripping of edematous epithelium from the cornea can temporarily clear the cornea. If the view through the cornea is compromised, trabeculotomy or combined trabeculotomy-&#173;trabeculectomy can be performed.</p>
			<p class="body-text">In approximately 80% of infants with PCG presenting from 3 months to 1 year of age, IOP is controlled with 1 or 2 &#173;angle surgeries. If the first procedure is not sufficient, at least 1 additional &#173;angle surgery is usually performed before a dif&#173;fer&#173;ent procedure is used.</p>
			<p class="body-text">When &#173;angle surgery is not successful in a child or is not indicated (as is the case in many forms of secondary glaucoma) and medical therapy is inadequate, additional surgical options include trabeculectomy with or without antifibrotic therapy (eg, mitomycin C [MMC]), tube shunt implantation, and cyclodestructive procedures.</p>
			<p class="body-text">Reported success rates for trabeculectomy vary considerably by surgical technique and type of glaucoma and decrease as the length of follow-up increases. Patients younger than 1 year and &#173;those who are aphakic are more prone to treatment failure. Although the success rate of trabeculectomy improves with the use of antifibrotics such as MMC, the long-&#173;term risk of bleb leaks and endophthalmitis also increases. Long-&#173;term risk is reduced by using a fornix-&#173;based rather than a limbus-&#173;based conjunctival flap. Ab interno trabeculectomy using a mechanical device such as Trabectome (NeoMedix, Tustin, CA) has been described in the treatment of pediatric glaucoma, but its use is still evolving.</p>
			<p class="body-text">The reported success rate of tube shunt implantation surgery with Molteno (Molteno Ophthalmic Limited, Dunedin, New Zealand), Baerveldt (Johnson &amp; Johnson Vision, Santa Ana, CA), and Ahmed (New World Medical, Rancho Cucamonga, CA) devices varies between 54% and 85%. Although most &#173;children with implanted tube shunts must remain on adjunct topical medical therapy to control IOP &#173;after surgery, their blebs are thicker and are less prone to leaking and infection than &#173;those of patients who have under&#173;gone MMC-&#173;augmented trabeculectomy. Potential complications include shunt failure, tube erosion or migration, tube–&#173;cornea touch, cataract, restrictive strabismus, and endophthalmitis.</p>
			<p class="body-text">&#173;Laser cyclodestruction and cyclocryotherapy are generally reserved for resistant cases or &#173;those not amenable to other surgical procedures. &#173;These techniques decrease ciliary body production of aqueous humor, which results in lower IOP. <span class="italic">Cyclocryotherapy</span> (freezing the ciliary pro&#173;cesses through the sclera) may be successful, but the complication rate is high. Repeated applications are often necessary, and the risk of phthisis and blindness is significant (approximately 10%). <span class="italic">Transscleral cyclophotocoagulation</span> with the Nd:YAG or diode &#173;laser has a lower risk of complications. The short-&#173;term success rate is approximately 50%. Patients usually require more than one treatment.</p>
			<p class="body-text"><span class="italic">Endoscopic cyclophotocoagulation (ECP)</span> has been used in &#173;children with glaucomas that are difficult to treat. In ECP, a microendoscope applies &#173;laser energy to the ciliary pro&#173;cesses &#173;under direct visualization (<span class="xref-figure">Fig 22-8</span>). Success rates of up to 50% have been reported. Although this is an intraocular procedure, the complication rate may be lower than that of external cyclodestructive procedures. Use of the microendoscope is advantageous in eyes with abnormal anterior segment anatomy. Some studies have shown encouraging results for patients with aphakic glaucoma.</p>
			<p class="reference--journal--first">Chen TC, Chen PP, Francis BA, et&#160;al. Pediatric glaucoma surgery: a report by the American Acad&#173;emy of Ophthalmology. <span class="italic">Ophthalmology.</span> 2014;121(11):2107–2115.</p>
			<p class="reference--journal--last">Jayaram H, Scawn R, Pooley F, et&#160;al. Long-&#173;term outcomes of trabeculectomy augmented with mitomycin C undertaken within the first 2&#160;years of life. <span class="italic">Ophthalmology.</span> 2015;122(11):2216–2222.</p>
			<p class="h2">Medical Therapy</p>
			<p class="body-text--no-indent-">Generally, medical therapy for childhood glaucoma has lower success rates and greater risks than medical therapy for adult glaucomas. However, it serves several impor&#173;tant purposes in preoperative, postoperative, and long-&#173;term management, particularly in childhood glaucoma other than PCG. For example, medi&#173;cations can be used to lower IOP before surgery in order to reduce corneal edema and improve visualization during surgery. They may also be used &#173;after surgical procedures in order to provide additional IOP lowering.</p>
			<p class="body-text">Medical therapy for pediatric glaucoma also carries unique risks (<span class="xref-table">&#173;Table&#160;22-4</span>) &#173;because of the greater dose per body weight and the limited number of controlled clinical &#173;trials in &#173;children. Although punctal occlusion may be used to reduce systemic absorption of topical medi&#173;cations, it may be impractical in many young &#173;children. Limiting the frequency of eyedrop administration in young &#173;children may enhance adherence.</p>
			<p class="h3">Topical medi&#173;cations</p>
			<p class="body-text--no-indent-">Therapy with topical β-&#173;adrenergic antagonists, or β-&#173;blockers, may reduce IOP by 20%–30%. The major risks of this therapy are respiratory distress (caused by apnea or bronchospasm) and bradycardia, both of which occur mostly in small infants and in &#173;children with a history of bronchospasm. Betaxolol, a cardioselective β<span class="subscript CharOverride-2">1</span>-&#173;adrenergic antagonist, may be safer than a nonselective β-&#173;blocker for use in patients with asthma, but its pressure-&#173;lowering effect is less than that of nonselective agents.</p>
			<p class="body-text">Topical carbonic anhydrase inhibitors (CAIs) are effective in &#173;children, but they produce a smaller reduction in IOP (<span class="symbol">&lt;</span>15%) than do β-&#173;blockers. Corneal edema is a risk of&#160;topical CAIs; thus, they should be used with caution in &#173;children with coexisting corneal disease.</p>
			<p class="body-text">Prostaglandin analogues are effective in many pediatric patients. Their low systemic risk and once-&#173;daily dosing are advantageous.</p>
			<p class="body-text">Miotics are rarely used in &#173;children; perioperative pilocarpine, however, may facilitate &#173;angle surgery. Pilocarpine and echothiophate may be effective in patients with aphakic glaucoma.</p>
			<p class="body-text">The <span class="greek-tx CharOverride-3">α</span><span class="subscript CharOverride-2">2</span>-&#173;adrenergic agonist apraclonidine may be useful for short-&#173;term IOP reduction, but &#173;there is a high incidence of tachyphylaxis and allergy with use of this drug in young &#173;children. Brimonidine, another <span class="greek-tx CharOverride-3">α</span><span class="subscript CharOverride-2">2</span>-&#173;adrenergic agonist, effectively reduces IOP in some cases of pediatric glaucoma. Both medi&#173;cations can produce somnolence and respiratory depression in infants and young &#173;children. Infants and young &#173;children are particularly susceptible to brimonidine’s adverse effects. Therefore, brimonidine should be used with caution in &#173;children younger than 6&#160;years, and it is relatively contraindicated in &#173;children younger than 2&#160;years &#173;because of the risk of respiratory depression. &#173;There are similar limitations for the use of fixed-&#173;dose combination drugs such as brimonidine/timolol and brinzolamide/brimonidine in the pediatric population.</p>
			<p class="h3">Oral medi&#173;cations</p>
			<p class="body-text--no-indent-">Oral CAIs may be used effectively in &#173;children, particularly to delay the need for surgery or to clear the cornea before goniotomy. Their usefulness may be limited &#173;because of their systemic adverse effects (see &#173;Table&#160;22-4).</p>
			<p class="h1">Prognosis and Follow-Up</p>
			<p class="body-text--no-indent-">The prognosis for control of IOP and preservation of vision is poor for patients with PCG who pres&#173;ent at birth; at least half of &#173;these patients become legally blind. If the horizontal dia&#173;meter of the cornea is greater than 14&#160;mm at diagnosis, the visual prognosis is similarly poor. Up to 90% of cases in the “favorable prognostic group” (onset at 3–12 months of age) can be controlled with &#173;angle surgery and medi&#173;cations. The remaining 10%, and many of the remaining cases of primary and secondary glaucomas, often pres&#173;ent a lifelong challenge.</p>
			<p class="body-text">Vision loss in childhood glaucoma is multifactorial. It may result from corneal &#173;scarring and opacification, optic nerve damage, myopic astigmatism, and associated anisometropic and strabismic amblyopia. Myopia results from axial enlargement of the eye in the setting of high IOP; astigmatism may result from unequal expansion of the anterior segment or from corneal scarring. Careful treatment of refractive errors and amblyopia is necessary to optimize outcomes.</p>
			<p class="body-text">All cases of childhood glaucoma, as well as suspected but unconfirmed glaucoma, require diligent follow-up. &#173;After any surgical intervention or change in medical therapy, control of IOP should be assessed within a few weeks. Examination &#173;under sedation or anesthesia is often necessary in &#173;children for accurate assessment. The IOP should be considered not as an isolated finding but rather in conjunction with other mea&#173;sure&#173;ments obtained from the examination, including refractive error (mea&#173;sured serially), corneal di&#173;a&#173;meter, axial length, and cup–&#173;disc ratio. If the IOP is less than 20&#160;mm Hg &#173;under anesthesia but clinical evidence shows per&#173;sis&#173;tent corneal edema or enlargement, progressive optic nerve cupping, or myopic progression, further intervention should be pursued despite the IOP reading. In contrast, a young child who has an IOP of about 20&#160;mm Hg but shows evidence of clinical improvement may be observed carefully.</p>
			<p class="body-text">Long-&#173;term follow-up of &#173;children with glaucoma is impor&#173;tant. Relapse can occur years &#173;later, with elevated IOP and subsequent vision loss. Parents, and patients themselves as they become older, should be educated about the need for lifelong monitoring and management.</p>
		</div>
		</div>
		<div id="_idContainer008" class="_idGenObjectStyleOverride-1">
			<table id="table001" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-1" />
					<col class="_idGenTableRowColumn-2" />
					<col class="_idGenTableRowColumn-1" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table _1-BCSC-table-title" colspan="3">
							<p class="table-title"><span class="table-number">Table&#160;22-1</span> Classification of Childhood Glaucoma</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table _4-BCSC-table-body-first-row CellOverride-1" />
						<td class="Basic-Table _4-BCSC-table-body-first-row CellOverride-1">
							<p class="table-head">Primary childhood glaucoma</p>
						</td>
						<td class="Basic-Table _4-BCSC-table-body-first-row CellOverride-1" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Primary congenital glaucoma (PCG)</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1 ParaOverride-10">Neonatal or newborn onset (age 0–1 month)</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1 ParaOverride-10">Infantile onset (age 1–24 months)</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-indent-1 ParaOverride-10">Late-&#173;onset or late-&#173;recognized (age <span class="symbol">≥</span>24 months)</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Juvenile open-&#173;angle glaucoma (JOAG)</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table _5-BCSC-table-body CellOverride-2" />
						<td class="Basic-Table _5-BCSC-table-body CellOverride-2">
							<p class="table-head">Secondary childhood glaucoma</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body CellOverride-2" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Glaucoma associated with nonacquired ocular anomalies</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Glaucoma associated with nonacquired systemic disease or syndrome</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Glaucoma associated with acquired condition</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table _7-BCSC-table-body-last-row" />
						<td class="Basic-Table _7-BCSC-table-body-last-row">
							<p class="table-body ParaOverride-9">Glaucoma following cataract surgery</p>
						</td>
						<td class="Basic-Table _7-BCSC-table-body-last-row" />
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-8">
						<td class="Basic-Table _5-BCSC-table-body CellOverride-3" colspan="3">
							<p class="table-source-note">Information from Beck AD, Chang TCP, Freedman SF. Definition, classification, differential diagnosis. <br />In: Weinreb RN, Grajewski AL, Papadopoulos M, Grigg J, Freedman S, eds. <span class="table-source-emphasis">Childhood Glaucoma.</span> <br />Amsterdam: Kugler Publications; 2013:3–10. <span class="table-source-emphasis">World Glaucoma Association Consensus Series—9.</span></p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div id="_idContainer009" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 22-1</span> Childhood Glaucoma Research Network/World Glaucoma Association algorithm for the classification of childhood glaucoma. AL = axial length; C/D = cup–disc; JOAG = juvenile open-angle glaucoma; <span class="xref-table CharOverride-4">ROP = retinopathy of prematurity; </span>VF = visual field. <span class="figure-source-note">(Courtesy of Allen Beck, MD, and Ta Chen Peter Chang, MD; </span><a href="http://www.gl-foundation.org/"><span class="figure-source-note">www.gl-foundation.org/</span></a><span class="figure-source-note">.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer010" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C22_p277-292-web-resources/image/AAX-10141.png" alt="" />
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer013">
				<div id="_idContainer011" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 22-2</span> Primary congenital glaucoma, right eye. The cornea is enlarged. <span class="figure-source-note">(Courtesy of Gregg T. Lueder, MD.)</span></p>
				</div>
				<div id="_idContainer012" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C22_p277-292-web-resources/image/AAX-6891.jpg" alt="" />
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer016">
				<div id="_idContainer014" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C22_p277-292-web-resources/image/AAX-2310.png" alt="" />
				</div>
				<div id="_idContainer015" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 22-3</span> <span class="figure-caption-bold">A,</span> Breaks in Descemet membrane (Haab striae), right eye. <span class="figure-caption-bold">B,</span> Retroillumination, same eye.</p>
				</div>
			</div>
		</div>
		<div id="_idContainer017" class="_idGenObjectStyleOverride-1">
			<table id="table002" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-9" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table _1-BCSC-table-title">
							<p class="table-title"><span class="table-number">Table&#160;22-2</span> Differential Diagnosis of Signs in Primary Congenital Glaucoma</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table _4-BCSC-table-body-first-row CellOverride-1">
							<p class="table-head">Conditions sharing signs of epiphora and red eye</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Conjunctivitis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Congenital nasolacrimal duct obstruction</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Corneal epithelial defect/abrasion</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Keratitis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Ocular inflammation (eg, due to uveitis, trauma, foreign body)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Epiblepharon with eyelash touch</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-10">
						<td class="Basic-Table _5-BCSC-table-body CellOverride-4">
							<p class="table-head">Conditions sharing sign of corneal edema or opacification</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Corneal dystrophies: congenital hereditary endothelial dystrophy, posterior polymorphous <br />dystrophy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Obstetric birth trauma with Descemet tears</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Storage diseases: mucopolysaccharidoses, cystinosis, sphingolipidosis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Congenital anomalies: sclerocornea, Peters anomaly, choristomas</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Keratitis (eg, secondary to maternal rubella, herpes, phlyctenules)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Keratomalacia (from vitamin A deficiency)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Skin disorders affecting the cornea: congenital ichthyosis, congenital dyskeratosis</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Idiopathic (diagnosis of exclusion only)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-10">
						<td class="Basic-Table _5-BCSC-table-body CellOverride-4">
							<p class="table-head">Conditions sharing sign of corneal enlargement</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Axial myopia</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Megalocornea</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-10">
						<td class="Basic-Table _5-BCSC-table-body CellOverride-4">
							<p class="table-head">Conditions sharing sign of optic nerve cupping (real or apparent)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Physiologic optic nerve cupping</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Cupping associated with prematurity, periventricular leukomalacia</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Optic nerve coloboma or pit</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Optic atrophy</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-5">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body ParaOverride-9">Optic nerve hypoplasia</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-7">
						<td class="Basic-Table _7-BCSC-table-body-last-row">
							<p class="table-body ParaOverride-9">Optic nerve malformation</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-12">
						<td class="Basic-Table _8-BCSC-table-note CellOverride-3">
							<p class="table-source-note">Adapted with permission from Buckley EG. Primary congenital open-&#173;angle glaucoma. In: Kahook M, Schuman J, eds. <span class="table-source-emphasis">Chandler and Grant’s Glaucoma.</span> 5th&#160;ed. Thorofare, NJ: Slack Incorporated; 2013.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer020">
				<div id="_idContainer018" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C22_p277-292-web-resources/image/KIN00807.png" alt="" />
				</div>
				<div id="_idContainer019" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 22-4</span> <span class="figure-caption-bold">A,</span> The anterior chamber angle of a normal infant eye, as seen by direct gonioscopy with a Koeppe lens. <span class="figure-caption-bold">B,</span> Typical appearance of the anterior chamber angle of an infant with primary congenital glaucoma. Note the scalloped appearance of the peripheral iris. The anterior iris insertion obscures the scleral spur. <span class="figure-source-note">(Courtesy of Ken K. Nischal, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer023">
				<div id="_idContainer021" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C22_p277-292-web-resources/image/AAX-10142.png" alt="" />
				</div>
				<div id="_idContainer022" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 22-5</span> Optic nerve changes after treatment of congenital glaucoma. <span class="figure-caption-bold">A,</span> Preoperative enlarged optic disc cup. <span class="figure-caption-bold">B,</span> Reduction in disc cupping after intraocular pressure is reduced by goniotomy. <span class="figure-source-note">(Reproduced from Mochizuki H, Lesley AG, Brandt JD. Shrinkage of the scleral canal during cupping reve</span><span class="figure-source-note">r</span><span class="figure-source-note">sal in children. </span><span class="figure-source-emphasis">Ophthalmology.</span><span class="figure-source-note"> 2011;118(10):2009.)</span></p>
				</div>
			</div>
		</div>
		<div id="_idContainer024" class="Basic-Text-Frame">
			<table id="table003" class="No-Table-Style TableOverride-1">
				<colgroup>
					<col class="_idGenTableRowColumn-13" />
					<col class="_idGenTableRowColumn-13" />
				</colgroup>
				<tbody>
					<tr class="No-Table-Style _idGenTableRowColumn-3">
						<td class="No-Table-Style _1-BCSC-table-title" colspan="2">
							<p class="table-title"><span class="table-number">&#173;Table&#160;22-3</span> Nonacquired Conditions Associated With Secondary Glaucoma</p>
						</td>
					</tr>
					<tr class="No-Table-Style _idGenTableRowColumn-14">
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-5">
							<p class="table-head ParaOverride-11">Ocular Anomalies</p>
							<p class="table-indent-1 ParaOverride-12">Anterior segment abnormalities</p>
							<p class="table-indent-3 ParaOverride-13">Aniridia</p>
							<p class="table-indent-3 ParaOverride-13">Axenfeld-Rieger syndrome</p>
							<p class="table-indent-3 ParaOverride-13">Congenital iris ectropion</p>
							<p class="table-indent-3 ParaOverride-13">Microcornea</p>
							<p class="table-indent-3 ParaOverride-13">Microspherophakia</p>
							<p class="table-indent-3 ParaOverride-13">Peters anomaly</p>
							<p class="table-indent-3 ParaOverride-13">Sclerocornea</p>
							<p class="table-indent-3 ParaOverride-13">Tumors of the iris</p>
							<p class="table-indent-1 ParaOverride-12">Posterior segment abnormalities</p>
							<p class="table-indent-3 ParaOverride-13">Familial exudative vitreoretinopathy</p>
							<p class="table-indent-3 ParaOverride-13">Persistent fetal vasculature </p>
							<p class="table-indent-3 ParaOverride-13">Retinopathy of prematurity </p>
							<p class="table-indent-1 ParaOverride-12">Tumors of the retina or ciliary body</p>
						</td>
						<td class="No-Table-Style _4-BCSC-table-body-first-row CellOverride-6">
							<p class="table-head ParaOverride-11">Systemic Disease or Syndrome</p>
							<p class="table-indent-1 ParaOverride-12">Sturge-Weber syndrome</p>
							<p class="table-indent-1 ParaOverride-12">Neurofibromatosis type 1 </p>
							<p class="table-indent-1 ParaOverride-12">Lowe (oculocerebrorenal) syndrome</p>
							<p class="table-indent-1 ParaOverride-12">Lens-associated disorders</p>
							<p class="table-indent-3 ParaOverride-13">Homocystinuria</p>
							<p class="table-indent-3 ParaOverride-13">Marfan syndrome</p>
							<p class="table-indent-3 ParaOverride-13">Weill-Marchesani syndrome</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer025" class="_idGenObjectStyleOverride-1">
			</div>
		</div>
		<div id="_idContainer026" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 22-6</span> Goniotomy needle with its tip in the trabecular meshwork. The trabecular meshwork to the left of the needle has been incised. <span class="figure-source-note">(Courtesy of Ken K. Nischal, MD.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer029">
				<div id="_idContainer027" class="_idGenObjectStyleOverride-1">
					<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C22_p277-292-web-resources/image/AAX-8012.png" alt="" />
				</div>
				<div id="_idContainer028" class="Basic-Text-Frame">
					<p class="figure-caption"><span class="figure-number">Figure 22-7</span> Trabeculotomy. <span class="figure-caption-bold">A,</span> The trabeculotome has entered the Schlemm canal. <span class="figure-caption-bold">B,</span> The trabeculotome has been rotated into the anterior chamber. <span class="figure-source-note">(Courtesy of Steven M. Archer, MD.)</span></p>
				</div>
			</div>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer030" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C22_p277-292-web-resources/image/AAX-8011.jpg" alt="" />
			</div>
		</div>
		<div id="_idContainer031" class="Basic-Text-Frame">
			<p class="figure-caption"><span class="figure-number">Figure 22-8</span> Endoscopic view of the ciliary processes during endoscopic cyclophotocoagulation. The white structure at the bottom right of the photo is the lens. <span class="figure-source-note">(Courtesy of Endo Optiks, Little Silver, NJ.)</span></p>
		</div>
		<div class="_idGenObjectLayout-1">
			<div id="_idContainer032" class="_idGenObjectStyleOverride-1">
				<img class="_idGenObjectAttribute-2" src="BCSC1819_S06_C22_p277-292-web-resources/image/AAX-3592.jpg" alt="" />
			</div>
		</div>
		<div id="_idContainer033" class="_idGenObjectStyleOverride-1">
			<table id="table004" class="Basic-Table">
				<colgroup>
					<col class="_idGenTableRowColumn-15" />
					<col class="_idGenTableRowColumn-16" />
					<col class="_idGenTableRowColumn-17" />
					<col class="_idGenTableRowColumn-16" />
					<col class="_idGenTableRowColumn-18" />
				</colgroup>
				<tbody>
					<tr class="Basic-Table _idGenTableRowColumn-19">
						<td class="Basic-Table _1-BCSC-table-title" colspan="5">
							<p class="table-title"><span class="table-number">&#173;Table&#160;22-4</span> Systemic and Ocular Adverse Effects of Glaucoma Medi&#173;cations in&#160;&#173;Children</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-3">
						<td class="Basic-Table _3-BCSC-table-column-head CellOverride-2">
							<p class="table-column-head">Drug</p>
						</td>
						<td class="Basic-Table _3-BCSC-table-column-head CellOverride-2" />
						<td class="Basic-Table _3-BCSC-table-column-head CellOverride-2">
							<p class="table-column-head">Adverse Effects</p>
						</td>
						<td class="Basic-Table _3-BCSC-table-column-head CellOverride-2" />
						<td class="Basic-Table _3-BCSC-table-column-head CellOverride-2">
							<p class="table-column-head">Precautions</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-4">
						<td class="Basic-Table _4-BCSC-table-body-first-row _idGenCellOverride-1" colspan="5">
							<p class="table-head"><span class="CharOverride-5">β</span>-&#173;Adrenergic antagonists</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-20">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body">Betaxolol, carteolol, levobunolol, metipranolol, timolol hemihydrate, timolol maleate</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body">Hypotension, bradycardia, bronchospasm, apnea</p>
							<p class="table-body">Hallucinations</p>
							<p class="table-body">Masking of hypoglycemia in diabetic &#173;children</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body">Avoid in premature or small infants</p>
							<p class="table-body">Use with caution in infants, &#173;children with asthma or cardiac disease</p>
							<p class="table-body">Select lower concentrations</p>
							<p class="table-body">Use punctal occlusion</p>
							<p class="table-body">Consider cardioselective <span class="greek--tb-">β</span>-&#173;blocker to reduce risk of bronchospasm</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-10">
						<td class="Basic-Table _5-BCSC-table-body CellOverride-4" colspan="5">
							<p class="table-head">Prostaglandin analogues</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-21">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body">Bimatoprost, latanoprost, tafluprost, travoprost</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body">May exacerbate uveitis</p>
							<p class="table-body">Risk of ret&#173;i&#173;nal detachment in Sturge-&#173;Weber syndrome</p>
							<p class="table-body">Low systemic risk, pos&#173;si&#173;ble sleep disturbance or exacerbation of asthma</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body">Avoid in patients with uveitis</p>
							<p class="table-body">Use with caution following intraocular surgery</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-10">
						<td class="Basic-Table _5-BCSC-table-body CellOverride-4" colspan="5">
							<p class="table-head"><span class="CharOverride-5">α</span><span class="subscript CharOverride-2">2</span>-&#173;Adrenergic agonists</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-20">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body">Apraclonidine, brimonidine</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body">Apraclonidine: tachyphylaxis, allergy</p>
							<p class="table-body">Apraclonidine and brimonidine: hypotension, bradycardia, hypothermia, CNS depression, coma</p>
							<p class="table-body">Risks are greater with brimonidine</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body">Brimonidine relatively contraindicated in &#173;children <span class="symbol">&lt;</span>2&#160;years of age</p>
							<p class="table-body">Caution in &#173;children <span class="symbol">&lt;</span>6&#160;years of age or <span class="symbol">&lt;</span>20&#160;kg</p>
							<p class="table-body">Use low dosage</p>
							<p class="table-body">Avoid in patients with cardiovascular disease, hepatic or renal impairment</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table _5-BCSC-table-body CellOverride-2" colspan="5">
							<p class="table-head">Topical CAIs</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-21">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body">Brinzolamide, dorzolamide</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body">Metabolic acidosis (rare)</p>
							<p class="table-body">Stevens-&#173;Johnson syndrome</p>
							<p class="table-body">Corneal edema</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body">Contraindicated in infants with renal insufficiency</p>
							<p class="table-body">Contraindicated in sulfonamide hypersensitivity</p>
							<p class="table-body">Monitor infant feeding, weight gain</p>
							<p class="table-body">Caution in corneal disease</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-10">
						<td class="Basic-Table _5-BCSC-table-body CellOverride-4" colspan="5">
							<p class="table-head">Oral CAIs</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-22">
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body">Acetazolamide, methazolamide</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body">Metabolic acidosis</p>
							<p class="table-body">Stevens-&#173;Johnson syndrome</p>
							<p class="table-body">Headache, nausea, dizziness, paresthesia</p>
							<p class="table-body">Growth suppression, failure to thrive, weight loss</p>
							<p class="table-body">Bed-&#173;wetting</p>
						</td>
						<td class="Basic-Table _5-BCSC-table-body" />
						<td class="Basic-Table _5-BCSC-table-body">
							<p class="table-body">Contraindicated in renal insufficiency, hypokalemia, hyponatremia</p>
							<p class="table-body">Contraindicated in sulfonamide hypersensitivity</p>
							<p class="table-body">Monitor for metabolic acidosis</p>
							<p class="table-body">Monitor infant feeding, weight gain</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-11">
						<td class="Basic-Table _5-BCSC-table-body" colspan="5">
							<p class="table-head">Parasympathomimetic <br />agents (miotics)</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-23">
						<td class="Basic-Table _7-BCSC-table-body-last-row">
							<p class="table-body">Echothiophate, pilocarpine</p>
						</td>
						<td class="Basic-Table _7-BCSC-table-body-last-row" />
						<td class="Basic-Table _7-BCSC-table-body-last-row">
							<p class="table-body">Risk of pupillary block</p>
							<p class="table-body">Paradoxical rise in IOP</p>
							<p class="table-body">Echothiophate: diarrhea, urinary incontinence, cardiac arrhythmia, weakness, headache, fatigue, iris cysts</p>
							<p class="table-body">Pilocarpine: bronchospasm, hypertension, vomiting, diarrhea, dizziness, weakness, headache</p>
						</td>
						<td class="Basic-Table _7-BCSC-table-body-last-row" />
						<td class="Basic-Table _7-BCSC-table-body-last-row">
							<p class="table-body">Avoid in patients with uveitis</p>
							<p class="table-body">Use with caution in cardiac disease, asthma, urinary tract obstruction</p>
							<p class="table-body">Limit dosage and use lower concentrations</p>
							<p class="table-body">Echothiophate: avoid succinylcholine</p>
							<p class="table-body">Consider stopping before general anesthesia</p>
						</td>
					</tr>
					<tr class="Basic-Table _idGenTableRowColumn-6">
						<td class="Basic-Table CellOverride-7" colspan="5">
							<p class="table-footnote">CAIs = carbonic anhydrase inhibitors.</p>
						</td>
					</tr>
				</tbody>
			</table>
		</div>
	</body>
</html>
